Compare
Calidi Biotherapeutics, Inc. vs AIM ImmunoTech Inc. vs Eloxx Pharmaceuticals, Inc. vs Inmune Bio, Inc.
| Latest fiscal year | Calidi Biotherapeutics, Inc. CLDI | AIM ImmunoTech Inc. AIM | Eloxx Pharmaceuticals, Inc. ELOX | Inmune Bio, Inc. INMB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $88.0K | $0 | $50.0K |
| Revenue growth (YoY) | n/a | -48.2% | -100.0% | +257.1% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/m |
| Net margin | n/a | n/m | n/a | n/m |
| Net income | -$19.91M | -$13.96M | -$6.00M | -$45.93M |
| EPS (Diluted) | -$5.95 | -$8.62 | -$0.49 | -$1.86 |
| Operating cash flow | -$21.29M | -$10.96M | -$6.33M | -$22.58M |
| Free cash flow | n/a | n/a | n/a | -$23.62M |
| Cash & equivalents | n/a | $2.98M | $4.79M | $24.75M |
| Total assets | $8.86M | $5.78M | $5.27M | $32.35M |
| Total liabilities | $5.10M | $15.56M | $17.18M | $8.83M |
| Shareholders' equity | $3.76M | -$9.78M | -$11.91M | $23.52M |
| Return on year-end equity | -529.6% | n/a | n/a | -195.3% |
| Shares outstanding | 7.22M | 3.07M | 4.79M | 26.59M |
Revenue, most recent five fiscal years
| Fiscal year | Calidi Biotherapeutics, Inc. | AIM ImmunoTech Inc. | Eloxx Pharmaceuticals, Inc. | Inmune Bio, Inc. |
|---|---|---|---|---|
| Latest | $45.0K Ended 2022-12-31 | $88.0K Ended 2025-12-31 | $0 Ended 2025-12-31 | $50.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $170.0K Ended 2024-12-31 | $6.36M Ended 2024-12-31 | $14.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $202.0K Ended 2023-12-31 | $0 Ended 2023-12-31 | $155.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $141.0K Ended 2022-12-31 | n/a | $374.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $135.0K Ended 2021-12-31 | n/a | $181.0K Ended 2021-12-31 |